Cargando…

Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity

BACKGROUND: Obesity in adolescence presents a major public health challenge, often leading to obesity in adulthood with associated chronic disease. OBJECTIVES: This study aimed to perform a population pharmacokinetic and exposure‐response analysis of liraglutide by meta‐analysis of data from trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlsson Petri, Kristin C., Hale, Paula M., Hesse, Dan, Rathor, Naveen, Mastrandrea, Lucy D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519033/ https://www.ncbi.nlm.nih.gov/pubmed/33963681 http://dx.doi.org/10.1111/ijpo.12799

Ejemplares similares

Liraglutide effects in a paediatric (7‐11 y) population with obesity: A randomized, double‐blind, placebo‐controlled, short‐term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics
por: Mastrandrea, Lucy D., et al.
Publicado: (2019)

Comparable Liraglutide Pharmacokinetics in Pediatric and Adult Populations with Type 2 Diabetes: A Population Pharmacokinetic Analysis
por: Petri, Kristin C. Carlsson, et al.
Publicado: (2015)

OR33-01 Liraglutide for Weight Management in Pubertal Adolescents with Obesity: A Randomized Controlled Trial
por: Kelly, Aaron S, et al.
Publicado: (2020)

Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
por: Overgaard, Rune V., et al.
Publicado: (2016)

Liraglutide for Weight Management in Children and Adolescents With Prader–Willi Syndrome and Obesity
por: Diene, Gwenaëlle, et al.
Publicado: (2022)

Efficacy and safety of liraglutide in Indian adolescents with obesity
por: Kochar, I. S., et al.
Publicado: (2019)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Exposure–response analyses of liraglutide 3.0 mg for weight management
por: Wilding, J. P. H., et al.
Publicado: (2016)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
por: Jacobsen, Lisbeth V., et al.
Publicado: (2015)

The association between anti‐insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast‐acting insulin aspart in children and adolescents with type 1 diabetes
por: Biester, Torben, et al.
Publicado: (2020)

Clinical Impact of Liraglutide as a Treatment of Obesity
por: Alruwaili, Heshma, et al.
Publicado: (2021)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

Liraglutide restores impaired associative learning in individuals with obesity
por: Hanssen, Ruth, et al.
Publicado: (2023)

Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome
por: Kim, Yoo-Mi, et al.
Publicado: (2020)

Efficacy of Liraglutide in Obesity in Children and Adolescents: Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Cornejo-Estrada, Alejandra, et al.
Publicado: (2023)

Population pharmacokinetics and exposure–response analyses of varenicline in adolescent smokers
por: Fediuk, Daryl J., et al.
Publicado: (2021)

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus
por: Mader, Julia K., et al.
Publicado: (2016)

Liraglutide and obesity: a review of the data so far
por: Ladenheim, Ellen E
Publicado: (2015)

Effects of liraglutide on obesity-associated functional hypogonadism in men
por: Jensterle, M, et al.
Publicado: (2019)

Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial
por: Bensignor, Megan O., et al.
Publicado: (2021)

Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
por: Kim, Sun H., et al.
Publicado: (2013)

Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
por: Seo, Young-Gyun
Publicado: (2021)

Liraglutide with Lifestyle Intervention in Adolescents with Overweight/Obesity, Nonalcoholic Fatty Liver Disease, and Type II Diabetes Mellitus
por: Kohut, Taisa, et al.
Publicado: (2021)

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
por: Carlsson Petri, Kristin Cecilie, et al.
Publicado: (2018)

Treatment of an Adolescent Female With Nonalcoholic Steatohepatitis–Related Cirrhosis With Liraglutide
por: Yuen, Christina, et al.
Publicado: (2023)

Liraglutide-Induced Hepatotoxicity
por: Maor, Yaakov, et al.
Publicado: (2021)

Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity
por: Caputo, Marina, et al.
Publicado: (2021)

The Use of Liraglutide in Obese Patients With COVID-19: A Case Report
por: Hanada, Taliê Zanchetta Buani, et al.
Publicado: (2021)

FRI063 Effectiveness Of Liraglutide In Treating Obesity And Improving Hepatic Steatosis
por: Alfadda, Assim Abdulaziz, et al.
Publicado: (2023)

MON-605 Serum CD163, but Not Gal-3, Predicts Response to Liraglutide Therapy in Obese Patients
por: Mat, Arimin, et al.
Publicado: (2020)

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study
por: JENSTERLE, MOJCA, et al.
Publicado: (2016)

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial
por: Jensterle, Mojca, et al.
Publicado: (2017)

Liraglutide Treatment in a Morbidly Obese Adolescent with a MC4R Gene Variant: Side Effects Reduce Success
por: Çamtosun, Emine, et al.
Publicado: (2023)

Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study
por: Barnard-Kelly, Katharine, et al.
Publicado: (2022)

Liraglutide – Indian Experience
por: Anirban, Majumder, et al.
Publicado: (2018)

Injection site reaction induced by liraglutide use in a female patient with obesity
por: Ayhan, Ihsan, et al.
Publicado: (2023)

Efficacy of Intragastric Balloon versus Liraglutide as Bridge to Surgery in Super-Obese Patients
por: Martines, Gennaro, et al.
Publicado: (2023)

Liraglutide suppresses obesity and promotes browning of white fat via miR-27b in vivo and in vitro
por: Wang, Xing, et al.
Publicado: (2021)

The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
por: Mancini, Marcio C., et al.
Publicado: (2017)

Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
por: Zhao, Xu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_156h1hffkqnmnuf3e8rhpo37f1